Exactech

Duncan-Williams is out with its report today on Exactech (NASDAQ: EXAC), maintaining Buy. In a note to clients, Duncan-Williams writes, "We continue to believe that EXAC is undervalued, and we encourage investors to do due diligence on the company. Our investment thesis is focused on EXAC's...

According to Duncan-Williams, Exactech (NASDAQ: EXAC) announced the launch of the Proliant Polyaxial Pedicle Screw System for orthopedic and neurosurgeons. Duncan-Williams said that it is encouraged by this product launch as it represents the first spinal system developed in-house by EXAC. EXAC...

Duncan-Williams is out with its report on Exactech (NASDAQ: EXAC), reiterating Buy. In a note to clients, Duncan-Williams writes, "We are maintaining our 2011 revenue and EPS estimates of $207 million and $1.15, respectively. This represents 9% revenue growth and 34% EPS growth compared to 2010....